Lupu Mihai, Tudor Diana, Filip Adriana
Iuliu Hatieganu University of Medicine and Pharmacy, Department of Physiology, Cluj-Napoca, Romania.
Iuliu Hatieganu University of Medicine and Pharmacy, Department of Physiology, Cluj-Napoca, Romania.
Rev Port Cardiol. 2022 Dec;41(12):1037-1046. doi: 10.1016/j.repc.2021.09.022. Epub 2022 Oct 10.
Iron interactions with the cardiovascular system were proposed about half a century ago, yet a clear-cut understanding of this micronutrient and its intricacies with acute and chronic events is still lacking. In chronic heart failure, patients with decreased iron stores appear to benefit from intravenous administration of metallic formulations, whereas acute diseases (e.g., myocardial infarction, stroke) are barely studied in randomized controlled trials in humans. However, proof-of-concept studies have indicated that the dual redox characteristics of iron could be involved in atherosclerosis, necrosis, and ferroptosis. To this end, we sought to review the currently available body of literature pertaining to these temporal profiles of heart diseases, as well as the pathophysiologic mechanism by which iron enacts, underlining key points related to treatment options.
大约半个世纪前就有人提出铁与心血管系统之间的相互作用,但对于这种微量营养素及其与急性和慢性事件的复杂关系仍缺乏清晰的认识。在慢性心力衰竭中,铁储备减少的患者似乎从静脉注射金属制剂中获益,而急性疾病(如心肌梗死、中风)在人类随机对照试验中几乎未被研究。然而,概念验证研究表明,铁的双重氧化还原特性可能与动脉粥样硬化、坏死和铁死亡有关。为此,我们试图回顾目前关于这些心脏病时间特征的文献,以及铁发挥作用的病理生理机制,强调与治疗选择相关的关键点。